Safety and Complications of Long-Term Proton Pump Inhibitor Therapy: Getting Closer to the Truth

  • Douglas A. Corley
    Reprint requests Address requests for reprints to: Douglas A. Corley, MD, PhD, Kaiser Permanente, Division of Research, 2000 Broadway, Oakland, California 94612.
    Kaiser Permanente, Division of Research, Oakland, California
    Search for articles by this author
      See “Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin,” by Moayyedi P, Eikelboom JW, Bosch J, et al, on page 682.
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sachar H.
        • Vaidya K.
        • Laine L.
        Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis.
        JAMA Intern Med. 2014; 174: 1755-1762
        • Sigterman K.E.
        • van Pinxteren B.
        • Bonis P.A.
        • Lau J.
        • Numans M.E.
        Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
        Cochrane Database Syst Rev. 2013; Cd002095
        • Yang M.
        • He M.
        • Zhao M.
        • et al.
        Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review.
        Curr Med Res Opin. 2017; 33: 973-980
        • Freedberg D.E.
        • Kim L.S.
        • Yang Y.X.
        The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association.
        Gastroenterology. 2017; 152: 706-715
        • Vaezi M.F.
        • Yang Y.X.
        • Howden C.W.
        Complications of proton pump inhibitor therapy.
        Gastroenterology. 2017; 153: 35-48
        • Hansen K.E.
        • Nieves J.W.
        • Nudurupati S.
        • Metz D.C.
        • Perez M.C.
        Dexlansoprazole and esomeprazole do not affect bone homeostasis in healthy postmenopausal women.
        Gastroenterology. 2019; 156: 926-934.e926
        • Attwood S.E.
        • Ell C.
        • Galmiche J.P.
        • et al.
        Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies.
        Aliment Pharmacol Ther. 2015; 41: 1162-1174
        • Ho P.M.
        • Maddox T.M.
        • Wang L.
        • et al.
        Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.
        JAMA. 2009; 301: 937-944
        • O'Donoghue M.L.
        • Braunwald E.
        • Antman E.M.
        • et al.
        Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.
        Lancet. 2009; 374: 989-997
        • Landi S.N.
        • Sandler R.S.
        • Pate V.
        • Lund J.L.
        No increase in risk of acute myocardial infarction in privately insured adults prescribed proton pump inhibitors vs histamine-2 receptor antagonists (2002-2014).
        Gastroenterology. 2018; 154: 861-873.e866
        • Lochhead P.
        • Hagan K.
        • Joshi A.D.
        • et al.
        Association between proton pump inhibitor use and cognitive function in women.
        Gastroenterology. 2017; 153: 971-979.e974
        • Nguyen L.H.
        • Lochhead P.
        • Joshi A.D.
        • et al.
        No significant association between proton pump inhibitor use and risk of stroke after adjustment for lifestyle factors and indication.
        Gastroenterology. 2018; 154: 1290-1297.e1291
        • Hill A.B.
        The environment and disease: association or causation?.
        Proc Roy Soc Med. 1965; 58: 295-300
        • Lam J.R.
        • Schneider J.L.
        • Zhao W.
        • Corley D.A.
        Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency.
        JAMA. 2013; 310: 2435-2442
        • Moayyedi P.
        • Eikelboom J.W.
        • Bosch J.
        • et al.
        Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin.
        Gastroenterology. 2019; 157: 682-691
        • Rodriguez-Poncelas A.
        • Barcelo M.A.
        • Saez M.
        • Coll-de-Tuero G.
        Duration and dosing of proton pump inhibitors associated with high incidence of chronic kidney disease in population-based cohort.
        PLoS One. 2018; 13e0204231

      Linked Article